NAV as on 2026-07-17 · Equity · Other ETFs
AUM
₹14 Cr
1Y Return
-
3Y CAGR
-
5Y CAGR
-
Expense
0.12%
Risk
Very High
1Y Return
-
3Y CAGR
-
5Y CAGR
-
Since Inception
+36.3%
AI Fund Analysis
Get AI-powered verdict, strengths, risks, and SIP recommendations for this fund.
NAV History
Drag or scroll the chart to pan through history
52-Week NAV Range
93% from 52W low
Fund Information
Fund House
Mirae Asset Mutual Fund
Category
Equity - Other ETFs
Min SIP
₹500
Min Lumpsum
₹5,000
Portfolio Composition
Asset Allocation
Market Cap Split
Top Holdings
Sun Pharmaceuticals Industries Ltd
Healthcare
Apollo Hospitals Enterprise Ltd
Healthcare
Max Healthcare Institute Ltd Ordinary Shares
Healthcare
Divi's Laboratories Ltd
Healthcare
Dr Reddy's Laboratories Ltd
Healthcare
Cipla Ltd
Healthcare
Laurus Labs Ltd
Healthcare
Lupin Ltd
Healthcare
Fortis Healthcare Ltd
Healthcare
Torrent Pharmaceuticals Ltd
Healthcare
Sector Allocation
Fundamentals
P/E Ratio
40.14
P/B Ratio
5.54
Dividend Yield
0.58%
Price/Sale
5.90
Price/Cash Flow
29.90
Peer Comparison
| Fund | AUM (Cr) | Exp % | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| Mirae Asset Nifty 500 Healthcare ETF | 14 | 0.12 | - | - | - |
| Nippon India Pharma Dir Gr | 9,044 | 0.79 | +7.5% | +20.8% | +13.4% |
| ICICI Pru Pharma Healthcare Diag Dir Gr | 6,625 | 0.86 | +7.3% | +25.6% | +16.5% |
| SBI Healthcare Opportunities Dir Gr | 4,998 | 1.03 | +14.8% | +24.7% | +17.4% |
| DSP Healthcare Fund Dir Gr | 3,514 | 0.51 | +10.1% | +23.0% | +16.1% |
| Mirae Asset Healthcare Dir Gr | 3,253 | 0.44 | +13.3% | +24.6% | +15.6% |
| HDFC Pharma and Healthcare Dir Gr | 2,611 | 1.08 | +19.3% | - | - |
| Nippon India Nifty Pharma ETF | 1,622 | 0.18 | +13.6% | +22.8% | +12.5% |
| Tata India Pharma & Healthcare Dir Gr | 1,455 | 0.67 | +8.2% | +22.5% | +14.8% |
| UTI Healthcare Dir Gr | 1,308 | 1.31 | +12.7% | +26.4% | +15.4% |
What If I Had Invested?
NAV history not available for this range
Key Metrics
Risk-o-Meter
Low
Moderate
High
Very High
Rated as Very High risk
Disclaimer: Mutual fund investments are subject to market risks. Read all scheme related documents carefully. Past performance is not indicative of future returns. NAV data sourced from AMFI. This is not SEBI-registered investment advice.